Patent · US Active

Imidamide sphingosine kinase inhibitors

US9421177B2 · kind B2 · utility

1Cited by

1References

11Claims

0Family size

Assignee

University of Virginia Patent Foundation · US

Inventors

Kevin R. Lynch · Charlottesville, US
Timothy L. Macdonald · Charlottesville, US
Thomas P. Mathews · Gainesville, US
Andrew KENNEDY · Santa Clara, US
Yugesh Kharel · Charlottesville, US

Key dates

Filing date	Aug 16, 2010
Grant date	Aug 23, 2016
Priority date	—
Expiry date	Aug 16, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2603/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.